Large B-Cell Lymphoma Clinical Trial

Millennium C05013

INDICATION:
Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

TITLE:
An Open-Label, Randomized, Phase 2 study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patient with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

IRB NAME:
Western, IRB

STATUS:
Open to enrollment

PHASE:
3

PURPOSE:
To determine whether the addition of VELCADE to RCHOP improves progression-free survival in patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

ELIGIBILITY:
Candidates must:

• Be male or female aged 18 years or older
• Have previously untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell that has been classified as the non-GCB subtype
• At least one measurable tumor mass that is >1.5 cm in the long axis and >1.0 cm in the short axis
• Availability of a paraffin block with sufficient tumor tissue to allow for subtyping that can be submitted for central laboratory analysis
• No evidence of central nervous system lymphoma

DURATION:
2 visits per cycle; total of 6 cycles

CONTACT/ADDITIONAL INFO:
Isabella Rodrigues, PhD
Clinical Research Coordinator
908-277-8630